NCT06053333 Social Determinants of Health in Hepatobiliary Cancer Patients
| NCT ID | NCT06053333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Malignant Hepatobiliary Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-07-17 |
| Primary Completion | 2028-07-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-07-17 with a primary completion date of 2028-07-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates barriers to receiving care and risks associated with developing cancer among patients diagnosed with hepatobiliary cancer.
Eligibility Criteria
Inclusion Criteria: * Patients 18+ year of age with hepatobiliary cancers Exclusion Criteria: * Patients under 18 years of age
Contact & Investigator
Nguyen H. Tran, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06053333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Hepatobiliary Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06053333 currently recruiting?
Yes, NCT06053333 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06053333 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06053333 clinical trial?
NCT06053333 is sponsored by Mayo Clinic. The principal investigator is Nguyen H. Tran, M.D. at Mayo Clinic in Rochester. The trial plans to enroll 400 participants.